|
MX2020001776A
(es)
|
2017-08-15 |
2020-03-24 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
|
|
US11884645B2
(en)
|
2018-03-02 |
2024-01-30 |
Inflazome Limited |
Sulfonyl acetamides as NLRP3 inhibitors
|
|
EP3759090A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166632A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
US11834433B2
(en)
|
2018-03-02 |
2023-12-05 |
Inflazome Limited |
Compounds
|
|
US20210395241A1
(en)
*
|
2018-07-03 |
2021-12-23 |
Novartis Ag |
Nlrp modulators
|
|
SG11202101480XA
(en)
|
2018-08-15 |
2021-03-30 |
Inflazome Ltd |
Novel sulfonamideurea compounds
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
CN114008030A
(zh)
|
2019-06-21 |
2022-02-01 |
Ac免疫有限公司 |
用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
|
|
AU2020312800B2
(en)
|
2019-07-17 |
2026-04-23 |
Zomagen Biosciences Ltd |
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
|
|
WO2021009567A1
(en)
*
|
2019-07-17 |
2021-01-21 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
JP2022545407A
(ja)
*
|
2019-08-16 |
2022-10-27 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤として有用な大環状スルホニルアミド誘導体
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
JP2023501319A
(ja)
*
|
2019-11-07 |
2023-01-18 |
インフレイゾーム リミテッド |
神経変性疾患の処置および予防
|
|
CA3158123A1
(en)
*
|
2019-11-12 |
2021-05-20 |
Yonggang Wei |
Amide derivative and preparation method therefore and use thereof in medicine
|
|
CA3175729A1
(en)
|
2020-03-16 |
2021-09-23 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
CA3174837A1
(en)
|
2020-04-15 |
2021-10-21 |
Daniel Oehlrich |
Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway
|
|
EP4135842B1
(en)
|
2020-04-15 |
2024-10-23 |
JANSSEN Pharmaceutica NV |
Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway
|
|
US20230203064A1
(en)
|
2020-04-23 |
2023-06-29 |
Janssen Pharmaceutica Nv |
Tricyclic compounds as inhibitors of nlrp3
|
|
WO2021219784A1
(en)
|
2020-04-30 |
2021-11-04 |
Janssen Pharmaceutica Nv |
New triazinoindole compounds
|
|
KR20230016658A
(ko)
|
2020-05-28 |
2023-02-02 |
얀센 파마슈티카 엔.브이. |
화합물
|
|
US12624010B2
(en)
|
2020-06-19 |
2026-05-12 |
Ac Immune Sa |
Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
|
|
CN115989219B
(zh)
*
|
2020-06-29 |
2026-02-13 |
贝凯恩生物医疗技术有限公司 |
用于治疗炎症小体介导的肺部疾病的丙磺舒化合物
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US20240043450A1
(en)
|
2020-09-24 |
2024-02-08 |
Janssen Pharmaceutica Nv |
New compound
|
|
EP3974415A1
(en)
|
2020-09-24 |
2022-03-30 |
Janssen Pharmaceutica NV |
Nlrp3 modulators
|
|
CN114133345A
(zh)
*
|
2020-12-17 |
2022-03-04 |
顺毅宜昌化工有限公司 |
一种2-氯磺酰基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
|
|
CA3208414A1
(en)
|
2021-03-04 |
2022-09-09 |
Daniel Oehlrich |
4-amino-6-oxo-pyridazine derivatives modulating nlrp3
|
|
KR20230152016A
(ko)
|
2021-03-04 |
2023-11-02 |
얀센 파마슈티카 엔브이 |
Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CN116917282B
(zh)
*
|
2021-05-10 |
2026-08-11 |
康百达（四川）生物医药科技有限公司 |
酰胺衍生物及其应用
|
|
WO2023275230A1
(en)
|
2021-07-01 |
2023-01-05 |
Janssen Pharmaceutica Nv |
5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
|
|
CN115677616B
(zh)
*
|
2021-11-03 |
2024-10-18 |
中国药科大学 |
大环磺酰胺类化合物及其制备方法和医药用途
|
|
JP2025502732A
(ja)
|
2021-12-22 |
2025-01-28 |
エーシー・イミューン・エス・アー |
ジヒドロオキサゾール誘導体化合物
|
|
US20250109154A1
(en)
*
|
2022-01-27 |
2025-04-03 |
The University Of Tokyo |
Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis
|
|
CA3252822A1
(en)
|
2022-02-21 |
2023-08-24 |
Viva Star Biosciences (Suzhou) Co., Ltd. |
NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INTERLEUKIN-1 ACTIVITY INHIBITORS
|
|
JP2025524640A
(ja)
|
2022-07-14 |
2025-07-30 |
エーシー・イミューン・エス・アー |
Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
|
|
CN119907797A
(zh)
|
2022-09-23 |
2025-04-29 |
默沙东有限责任公司 |
用作nod样受体蛋白3抑制剂的酞嗪衍生物
|
|
AU2024280075A1
(en)
|
2023-06-02 |
2025-12-11 |
Merck Sharp & Dohme Llc |
5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
|
|
US20250223290A1
(en)
|
2023-12-14 |
2025-07-10 |
Merck Sharp & Dohme Llc |
Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
|
|
TW202535370A
(zh)
|
2023-12-14 |
2025-09-16 |
美商默沙東有限責任公司 |
作為nod樣受體蛋白3抑制劑之吲唑衍生物
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
TW202545527A
(zh)
|
2024-01-16 |
2025-12-01 |
英商諾得瑟拉公司 |
Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
|
|
CN122555708A
(zh)
|
2024-01-17 |
2026-08-11 |
Ac免疫有限公司 |
用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
|
|
CN122555707A
(zh)
|
2024-01-17 |
2026-08-11 |
Ac免疫有限公司 |
用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|
|
WO2026132518A1
(en)
|
2024-12-20 |
2026-06-25 |
Ac Immune Sa |
Heterocyclic compounds modulating the nlrp3 inflammasome pathway
|